Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects
Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)] is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in pati...
Saved in:
| Published in: | Drug metabolism and disposition Vol. 38; no. 9; p. 1514 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.09.2010
|
| Subjects: | |
| ISSN: | 1521-009X, 1521-009X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)] is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 h in six healthy male subjects receiving a single oral suspension dose of 200 mg of [(14)C]ticagrelor. Ticagrelor was rapidly absorbed with a maximum plasma concentration at 1.5 h. The major active metabolite, AR-C124910XX, is formed by O-deethylation. Exposure to AR-C124910XX was 29% of peak and 40% of overall exposure to ticagrelor. In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively). The ratio of radioactivity in plasma to whole blood was 1.69, suggesting that ticagrelor and its metabolites are largely restricted to the plasma space. Mean radioactivity recovery was 26.5% in urine and 57.8% in feces. Major circulating components in the plasma and feces were identified as ticagrelor and AR-C124910XX, whereas in urine the major components were metabolite M5 (AR-C133913XX) and its glucuronide conjugate M4. Levels of unchanged ticagrelor and AR-C124910XX were <0.05% in the urine, indicating that renal clearance of ticagrelor and AR-C124910XX is of minor importance. Interindividual variability was small in both urine and fecal extracts with only small quantitative differences. All 10 of the metabolites were fully or partially characterized and a full biotransformation pathway was proposed for ticagrelor, in which oxidative loss of the hydroxyethyl side chain from ticagrelor forms AR-C124910XX and a second oxidative pathway leads to N-dealkylation of ticagrelor, forming AR-C133913XX. |
|---|---|
| AbstractList | Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)] is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 h in six healthy male subjects receiving a single oral suspension dose of 200 mg of [(14)C]ticagrelor. Ticagrelor was rapidly absorbed with a maximum plasma concentration at 1.5 h. The major active metabolite, AR-C124910XX, is formed by O-deethylation. Exposure to AR-C124910XX was 29% of peak and 40% of overall exposure to ticagrelor. In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively). The ratio of radioactivity in plasma to whole blood was 1.69, suggesting that ticagrelor and its metabolites are largely restricted to the plasma space. Mean radioactivity recovery was 26.5% in urine and 57.8% in feces. Major circulating components in the plasma and feces were identified as ticagrelor and AR-C124910XX, whereas in urine the major components were metabolite M5 (AR-C133913XX) and its glucuronide conjugate M4. Levels of unchanged ticagrelor and AR-C124910XX were <0.05% in the urine, indicating that renal clearance of ticagrelor and AR-C124910XX is of minor importance. Interindividual variability was small in both urine and fecal extracts with only small quantitative differences. All 10 of the metabolites were fully or partially characterized and a full biotransformation pathway was proposed for ticagrelor, in which oxidative loss of the hydroxyethyl side chain from ticagrelor forms AR-C124910XX and a second oxidative pathway leads to N-dealkylation of ticagrelor, forming AR-C133913XX. Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)] is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 h in six healthy male subjects receiving a single oral suspension dose of 200 mg of [(14)C]ticagrelor. Ticagrelor was rapidly absorbed with a maximum plasma concentration at 1.5 h. The major active metabolite, AR-C124910XX, is formed by O-deethylation. Exposure to AR-C124910XX was 29% of peak and 40% of overall exposure to ticagrelor. In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively). The ratio of radioactivity in plasma to whole blood was 1.69, suggesting that ticagrelor and its metabolites are largely restricted to the plasma space. Mean radioactivity recovery was 26.5% in urine and 57.8% in feces. Major circulating components in the plasma and feces were identified as ticagrelor and AR-C124910XX, whereas in urine the major components were metabolite M5 (AR-C133913XX) and its glucuronide conjugate M4. Levels of unchanged ticagrelor and AR-C124910XX were <0.05% in the urine, indicating that renal clearance of ticagrelor and AR-C124910XX is of minor importance. Interindividual variability was small in both urine and fecal extracts with only small quantitative differences. All 10 of the metabolites were fully or partially characterized and a full biotransformation pathway was proposed for ticagrelor, in which oxidative loss of the hydroxyethyl side chain from ticagrelor forms AR-C124910XX and a second oxidative pathway leads to N-dealkylation of ticagrelor, forming AR-C133913XX.Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)] is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 h in six healthy male subjects receiving a single oral suspension dose of 200 mg of [(14)C]ticagrelor. Ticagrelor was rapidly absorbed with a maximum plasma concentration at 1.5 h. The major active metabolite, AR-C124910XX, is formed by O-deethylation. Exposure to AR-C124910XX was 29% of peak and 40% of overall exposure to ticagrelor. In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively). The ratio of radioactivity in plasma to whole blood was 1.69, suggesting that ticagrelor and its metabolites are largely restricted to the plasma space. Mean radioactivity recovery was 26.5% in urine and 57.8% in feces. Major circulating components in the plasma and feces were identified as ticagrelor and AR-C124910XX, whereas in urine the major components were metabolite M5 (AR-C133913XX) and its glucuronide conjugate M4. Levels of unchanged ticagrelor and AR-C124910XX were <0.05% in the urine, indicating that renal clearance of ticagrelor and AR-C124910XX is of minor importance. Interindividual variability was small in both urine and fecal extracts with only small quantitative differences. All 10 of the metabolites were fully or partially characterized and a full biotransformation pathway was proposed for ticagrelor, in which oxidative loss of the hydroxyethyl side chain from ticagrelor forms AR-C124910XX and a second oxidative pathway leads to N-dealkylation of ticagrelor, forming AR-C133913XX. |
| Author | Oliver, Stuart Hayes, Martin A Butler, Kathleen Teng, Renli |
| Author_xml | – sequence: 1 givenname: Renli surname: Teng fullname: Teng, Renli email: renli.teng@astrazeneca.com organization: Clinical Pharmacology, AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19850, USA. renli.teng@astrazeneca.com – sequence: 2 givenname: Stuart surname: Oliver fullname: Oliver, Stuart – sequence: 3 givenname: Martin A surname: Hayes fullname: Hayes, Martin A – sequence: 4 givenname: Kathleen surname: Butler fullname: Butler, Kathleen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20551239$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LAzEYhINU7IdePUpuXro1ySZtcizFLyh4seBtSbJvbMrupiZZsP_eSit4mmeYYQ4zRoMudIDQLSUzShl_qNv6CGRGSsYEuUAjKhgtCFEfg388ROOUdoRQzkt1hYaMCEFZqUZoszQpxH32oZvi2qccvelProWsTWh8aqdYdzWGbxvhN8LB4eyt_ozQhIh9h7egm7w94NSbHdicrtGl002Cm7NO0Obp8X31Uqzfnl9Xy3VhOVG5WBgFksi5lE4Ap0wzY5XkzEnnCIGFkVxIcM4YzSSnc6VqI4mgdlGWEphlE3R_2t3H8NVDylXrk4Wm0R2EPlULLtVcyONTE3R3bvamhbraR9_qeKj-nmA_nK5ing |
| CitedBy_id | crossref_primary_10_1007_s11095_021_03105_w crossref_primary_10_1007_s00228_018_2484_7 crossref_primary_10_1080_14656566_2024_2385135 crossref_primary_10_1111_jon_12714 crossref_primary_10_1002_ajh_25273 crossref_primary_10_1160_TH16_04_0273 crossref_primary_10_1517_17425255_2015_1037279 crossref_primary_10_1111_cts_70079 crossref_primary_10_2165_11599830_000000000_00000 crossref_primary_10_1007_s11239_021_02558_5 crossref_primary_10_1007_s40261_022_01154_6 crossref_primary_10_1016_j_iccl_2013_05_006 crossref_primary_10_1007_s00228_018_2427_3 crossref_primary_10_1161_CIRCGENETICS_110_958611 crossref_primary_10_1007_s40261_017_0554_8 crossref_primary_10_1093_eurheartj_ehv116 crossref_primary_10_3390_ijms21041391 crossref_primary_10_12793_tcp_2019_27_3_98 crossref_primary_10_1097_AAP_0000000000000223 crossref_primary_10_1177_1074248413499971 crossref_primary_10_7326_M22_1667 crossref_primary_10_1007_s40262_023_01243_5 crossref_primary_10_2217_epi_2021_0461 crossref_primary_10_1038_nrcardio_2014_156 crossref_primary_10_1002_bmc_5663 crossref_primary_10_2459_JCM_0000000000000677 crossref_primary_10_1111_fcp_12219 crossref_primary_10_1160_TH12_08_0588 crossref_primary_10_3390_jcm12031149 crossref_primary_10_1080_13880209_2020_1785510 crossref_primary_10_1136_heartjnl_2014_306695 crossref_primary_10_2217_pme_13_106 crossref_primary_10_1007_s11883_013_0371_3 crossref_primary_10_3389_fphar_2021_761814 crossref_primary_10_3390_ijms242417546 crossref_primary_10_3389_fphar_2017_00176 crossref_primary_10_1007_s40262_019_00758_0 crossref_primary_10_1111_bcp_12950 crossref_primary_10_1111_bcp_15422 crossref_primary_10_1111_1750_3841_15096 crossref_primary_10_1310_hpj4701_47 crossref_primary_10_1182_blood_2015_01_622928 crossref_primary_10_2174_0113816128309440240427102903 crossref_primary_10_1007_s00228_012_1436_x crossref_primary_10_1371_journal_pone_0186013 crossref_primary_10_1002_cpt_3067 crossref_primary_10_1124_dmd_111_039669 crossref_primary_10_1111_trf_12977 crossref_primary_10_2217_fca_10_89 crossref_primary_10_1016_j_clinthera_2014_06_024 crossref_primary_10_1080_14779072_2020_1792293 crossref_primary_10_3390_jcm14155536 crossref_primary_10_1002_cpt_407 crossref_primary_10_1177_1074248413511693 crossref_primary_10_1007_s12325_020_01423_w crossref_primary_10_3390_pharmaceutics13040524 crossref_primary_10_1177_1747519821991993 crossref_primary_10_1371_journal_pone_0218934 crossref_primary_10_1080_09537104_2016_1265921 crossref_primary_10_1002_phar_1477 crossref_primary_10_1111_j_1365_2710_2012_01367_x crossref_primary_10_1111_bcp_12026 crossref_primary_10_1111_jth_13511 crossref_primary_10_1208_s12249_021_02138_z crossref_primary_10_1586_ecp_12_17 crossref_primary_10_1007_s00228_013_1543_3 crossref_primary_10_1136_neurintsurg_2021_017638 crossref_primary_10_1111_jth_14282 crossref_primary_10_1007_s43440_021_00309_0 crossref_primary_10_3390_jcm11041124 crossref_primary_10_1007_s12539_024_00681_4 crossref_primary_10_1016_j_clinthera_2012_04_005 crossref_primary_10_1038_s41598_018_29619_9 crossref_primary_10_1093_jat_bkw039 crossref_primary_10_1038_s41598_020_59663_3 crossref_primary_10_1016_j_ijcard_2015_05_023 crossref_primary_10_1186_s13256_023_04174_8 crossref_primary_10_1185_03007995_2011_595780 crossref_primary_10_5482_HAMO_12_05_0003 crossref_primary_10_1055_s_0042_1753479 crossref_primary_10_1016_j_ijcard_2016_04_087 crossref_primary_10_1016_j_medengphy_2017_08_005 crossref_primary_10_1016_j_clinthera_2013_06_003 crossref_primary_10_15420_ecr_2025_12 crossref_primary_10_1080_17512433_2022_2121702 crossref_primary_10_1007_s40261_014_0205_2 crossref_primary_10_1016_j_molstruc_2021_130675 crossref_primary_10_2165_11630740_000000000_00000 crossref_primary_10_1136_bmjopen_2016_013218 crossref_primary_10_2147_DDDT_S435477 crossref_primary_10_3109_09537104_2014_959913 crossref_primary_10_1097_FJC_0000000000000076 crossref_primary_10_1007_s11239_012_0744_4 crossref_primary_10_1007_s12928_014_0277_1 crossref_primary_10_2165_11206850_000000000_00000 crossref_primary_10_1007_s11886_011_0208_z crossref_primary_10_1111_j_1538_7836_2011_04419_x crossref_primary_10_3389_fendo_2021_711906 crossref_primary_10_1007_s40262_023_01245_3 crossref_primary_10_1007_s00062_020_00910_5 crossref_primary_10_1111_jcpt_12130 crossref_primary_10_1002_bmc_4498 crossref_primary_10_3390_medicina56100519 crossref_primary_10_3810_pgm_2011_11_2498 crossref_primary_10_1111_bcp_12230 crossref_primary_10_1016_j_clinthera_2015_01_010 crossref_primary_10_1161_ATVBAHA_112_250720 crossref_primary_10_1097_AAP_0000000000000700 crossref_primary_10_1016_j_thromres_2017_12_016 crossref_primary_10_1111_jth_13627 crossref_primary_10_3389_fbioe_2023_1295406 crossref_primary_10_1080_00498254_2020_1731625 crossref_primary_10_3109_09537104_2012_748185 crossref_primary_10_1016_j_neurad_2022_11_010 crossref_primary_10_1097_CRD_0b013e3182099d86 crossref_primary_10_3389_fcvm_2021_707814 crossref_primary_10_1016_j_dmd_2025_100067 crossref_primary_10_1016_j_ejps_2016_11_004 crossref_primary_10_1177_0897190014568383 crossref_primary_10_1007_s40265_013_0126_z crossref_primary_10_1182_blood_2014_01_512723 crossref_primary_10_1002_jlcr_3085 crossref_primary_10_1093_bja_aet401 crossref_primary_10_1016_j_ahj_2010_10_043 crossref_primary_10_1007_s00228_012_1227_4 crossref_primary_10_1016_j_bmcl_2014_06_006 crossref_primary_10_1016_j_bmcl_2016_04_030 crossref_primary_10_1586_14779072_2013_820440 crossref_primary_10_1038_s41598_020_66557_x crossref_primary_10_1016_j_xphs_2019_03_028 crossref_primary_10_1177_0091270011415526 crossref_primary_10_1517_14656566_2011_550573 crossref_primary_10_1016_j_cll_2016_05_002 crossref_primary_10_3389_fphar_2019_00209 crossref_primary_10_1517_17425255_2012_717931 crossref_primary_10_1007_s00228_012_1369_4 crossref_primary_10_1007_s40262_015_0290_2 crossref_primary_10_1002_prp2_509 crossref_primary_10_2165_11630960_000000000_00000 crossref_primary_10_3390_antibiotics12030628 crossref_primary_10_1016_j_jchromb_2018_12_018 crossref_primary_10_1111_cns_70258 crossref_primary_10_1586_erc_12_1 crossref_primary_10_1016_j_microc_2025_114007 crossref_primary_10_1007_s11302_012_9294_7 crossref_primary_10_1161_CIRCINTERVENTIONS_112_972323 crossref_primary_10_1038_s41598_020_63199_x crossref_primary_10_2165_11640880_000000000_00000 crossref_primary_10_3390_pharmaceutics16101324 crossref_primary_10_1002_cpt_1177 crossref_primary_10_3389_fphys_2021_663170 crossref_primary_10_1007_s11910_023_01266_2 crossref_primary_10_1016_j_jlumin_2015_07_037 crossref_primary_10_1038_clpt_2011_223 crossref_primary_10_2217_bmm_11_4 crossref_primary_10_1161_CIRCINTERVENTIONS_116_004229 crossref_primary_10_1002_jcph_2014 crossref_primary_10_1007_s40262_020_00864_4 crossref_primary_10_1182_blood_2016_03_707844 crossref_primary_10_1093_chromsci_bmz001 crossref_primary_10_1016_j_jacc_2024_06_038 crossref_primary_10_2459_JCM_0b013e328364561b crossref_primary_10_2217_cpr_12_40 crossref_primary_10_1016_j_jacc_2013_02_058 crossref_primary_10_1093_eurheartj_ehae177 crossref_primary_10_3390_molecules26020278 crossref_primary_10_1007_s40262_023_01335_2 crossref_primary_10_1080_17512433_2017_1353909 crossref_primary_10_3109_21556660_2013_785413 crossref_primary_10_1093_eurheartj_ehv326 crossref_primary_10_1002_cpdd_1471 crossref_primary_10_1016_j_jacc_2014_03_031 crossref_primary_10_1080_17425255_2016_1244524 crossref_primary_10_1007_s10555_017_9679_8 crossref_primary_10_1111_jth_13680 crossref_primary_10_1007_s40265_018_0947_x crossref_primary_10_1016_j_crvasa_2011_12_004 crossref_primary_10_1016_j_jchromb_2019_05_013 crossref_primary_10_1080_14656566_2017_1421634 crossref_primary_10_1093_bja_aet584 crossref_primary_10_1007_s11886_023_01892_9 crossref_primary_10_1038_srep31838 crossref_primary_10_3390_ijms17030388 crossref_primary_10_1016_j_ejmech_2020_112767 crossref_primary_10_1016_j_ijpharm_2018_11_038 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1124/dmd.110.032250 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1521-009X |
| ExternalDocumentID | 20551239 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AALRI AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 NPM O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YHG ZGI ZXP ~KM 7X8 |
| ID | FETCH-LOGICAL-c409t-7b9e808688f5e412a2bc9842f8ff00e7b8458effbba2841699db8051c7338e2c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 237 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000281114800020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1521-009X |
| IngestDate | Sun Nov 09 13:12:53 EST 2025 Mon Jul 21 05:43:51 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c409t-7b9e808688f5e412a2bc9842f8ff00e7b8458effbba2841699db8051c7338e2c2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 20551239 |
| PQID | 748965811 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_748965811 pubmed_primary_20551239 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-Sep 20100901 |
| PublicationDateYYYYMMDD | 2010-09-01 |
| PublicationDate_xml | – month: 09 year: 2010 text: 2010-Sep |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Drug metabolism and disposition |
| PublicationTitleAlternate | Drug Metab Dispos |
| PublicationYear | 2010 |
| SSID | ssj0014439 |
| Score | 2.4539154 |
| Snippet | Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1514 |
| SubjectTerms | Adenosine - administration & dosage Adenosine - analogs & derivatives Adenosine - pharmacokinetics Administration, Oral Adult Chromatography, Liquid Humans Male Middle Aged Purinergic Antagonists - administration & dosage Purinergic Antagonists - pharmacokinetics Reference Values Tandem Mass Spectrometry Ticagrelor |
| Title | Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20551239 https://www.proquest.com/docview/748965811 |
| Volume | 38 |
| WOSCitedRecordID | wos000281114800020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV05T8MwFLaAMrBwH-WSB9QppomTNPaEKkTFAFWGFmWLYseWKtGk1C2i_57nJKUTYmDJEMmSZX9-73s3QnfUF55UUUik6wkSUM0JVzonoQL6zH2Xycrf8fYSDYcsSXjc5OaYJq1yLRMrQZ2X0vrIu7ZLCmhLz3uYfRA7NMoGV5sJGtuo5QOTsaCOkk0QIQiqQWJWQxGgEknTsxE0Wjef5jYB_t61eHZ_Z5eVlhkc_HN_h2i_oZe4X-PhCG2p4hh14ro_9crBo025lXFwB8ebztWrEzTuC1POKyHi4Ny21G2mYTl4qhYAl_eJmTo4K3KsvqStfywLXGps_eFgt4PpjycFrksrV9gshXXymFM0HjyNHp9JM3eBSLD2FiQSXDEwdRjToQo8mlEhOYN7ZFq7rooEC0KmtBYiozZqyXkuGDxuGYG9q6ikZ2inKAt1gbDUrta9QPaiPAwELNAMCI_qBZ6nfPjTRnh9ming2gYrskKVS5P-nGcbndc3ks7q_hspdYHmUZ9f_r34Cu3V4X6bFHaNWhretLpBu_JzMTHz2wov8B3Gr98kYsxL |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absorption%2C+distribution%2C+metabolism%2C+and+excretion+of+ticagrelor+in+healthy+subjects&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Teng%2C+Renli&rft.au=Oliver%2C+Stuart&rft.au=Hayes%2C+Martin+A&rft.au=Butler%2C+Kathleen&rft.date=2010-09-01&rft.issn=1521-009X&rft.eissn=1521-009X&rft.volume=38&rft.issue=9&rft.spage=1514&rft_id=info:doi/10.1124%2Fdmd.110.032250&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1521-009X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1521-009X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1521-009X&client=summon |